Table 1.

Clinical and histologic characteristics of the PBx study population

Group A (n = 20)Group B (n = 20)P
Baseline clinical and histologic variables
 Age, y68.3 ± 9.464.8 ± 9.20.2
 Suspicious DRE ( %)31.820.00.4
 Prostate volume (mL)50.4 ± 29.052.6 ± 16.90.7
 Total PSA levels (ng/mL)7.7 ± 2.78.2 ± 5.90.7
 PSA density (ng/mL*mL)0.2 ± 0.10.2 ± 0.30.9
 International Prostate Symptom Score (I-PSS)12.1 ± 10.315.8 ± 10.50.6
 Flow max (mL/s)13.0 ± 7.110.4 ± 4.40.1
 Post-void residual (mL)39.3 ± 29.941.0 ± 20.90.8
 Histologic grading of prostatic inflammation (G≥2)3/20 (15%)4/20 (20%)0.8
 Aggressiveness of prostatic inflammation (A≥2)2/20 (10%)3/20 (15%)0.8
Clinical and histologic variables at second biopsy
 Prostate volume (mL)51.3 ± 27.854.1 ± 12.70.1
 Histologic grading of prostatic inflammation (G≥2)6/20 (30%)9/20 (45%)0.06
 Aggressiveness of prostatic inflammation (A≥2)5/20 (25%)7/20 (35%)0.40
Biopsy Gleason score
 ≤613 (65%)
 75 (25%)
 ≥82 (10%)